441 related articles for article (PubMed ID: 10603717)
1. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR.
Sharma A; Sharma VK; Rajwanshi A; Das A; Kaur I; Kumar B
Lepr Rev; 1999 Sep; 70(3):281-6. PubMed ID: 10603717
[TBL] [Abstract][Full Text] [Related]
2. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients.
Shetty VP; Suchitra K; Uplekar MW; Antia NH
Lepr Rev; 1992 Dec; 63(4):329-36. PubMed ID: 1479872
[TBL] [Abstract][Full Text] [Related]
3. Higher incidence of viable Mycobacterium leprae within the nerve as compared to skin among multibacillary leprosy patients released from multidrug therapy.
Shetty VP; Suchitra K; Uplekar MW; Antia NH
Lepr Rev; 1997 Jun; 68(2):131-8. PubMed ID: 9217352
[TBL] [Abstract][Full Text] [Related]
4. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
5. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
6. Viability and drug sensitivity of M. leprae isolated from long-term WHO/MDT treated multibacillary leprosy patients.
Habtemariam H
Lepr Rev; 1999 Mar; 70(1):43-6. PubMed ID: 10405543
[No Abstract] [Full Text] [Related]
7. Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India.
Narang T; Bishnoi A; Dogra S; Saikia UN; Kavita
Am J Trop Med Hyg; 2019 Jan; 100(1):24-30. PubMed ID: 30298809
[TBL] [Abstract][Full Text] [Related]
8. Two microbiological relapses in a patient with lepromatous leprosy.
Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
10. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
11. Viability of Mycobacterium leprae in skin and peripheral nerves and persistence of nerve destruction in multibacillary patients after 2 years of multidrug therapy.
Job CK; Jayakumar J; Aschhoff M; Mathan MM
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):44-50. PubMed ID: 8627112
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
13. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
Kumar A; Girdhar A; Girdhar BK
Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
[TBL] [Abstract][Full Text] [Related]
14. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT.
Shetty VP; Wakade AV; Ghate SD; Pai VV; Ganapati RR; Antia NH
Lepr Rev; 2005 Sep; 76(3):241-52. PubMed ID: 16248211
[TBL] [Abstract][Full Text] [Related]
15. Childhood leprosy in a tertiary-care hospital in Delhi, India: a reappraisal in the post-elimination era.
Singal A; Sonthalia S; Pandhi D
Lepr Rev; 2011 Sep; 82(3):259-69. PubMed ID: 22125934
[TBL] [Abstract][Full Text] [Related]
16. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
[TBL] [Abstract][Full Text] [Related]
17. In leprosy the presence of mycobacteria in the nerve is an essential factor in the cycle and spectrum of Mycobacterium leprae infection.
Negesse Y; Beimnet K; Miko T; Wondimus A; Berhan TY
Lepr Rev; 1993 Jun; 64(2):104-9. PubMed ID: 8341112
[TBL] [Abstract][Full Text] [Related]
18. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
19. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia.
Guerrero-Guerrero MI; Muvdi-Arenas S; León-Franco CI
Lepr Rev; 2012 Sep; 83(3):247-60. PubMed ID: 23356026
[TBL] [Abstract][Full Text] [Related]
20. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
